ArticleFrontiers in molecular biosciences2026
Prognostic impact of the lymph node yield on survival in patients with stage I lung adenocarcinoma receiving sublobar resection.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: It remains controversial regarding the prognostic impact and therapeutic implications for immunotherapy of lymph node yield (LNY) during sublobar resection (SR) on stage I lung adenocarcinoma (LUAD). Methods: We analyzed a retrospective cohort of 400 patients with stage I LUAD who underwent SR, with peripheral blood samples prospectively collected for detecting inflammatory cytokines (IFCs). The effect of different LNY (≥4 vs. <4 nodes) on survival and IFC change was evaluated. Consensus clustering analyses were performed using data from The Cancer Genome Atlas (TCGA) and our validation cohort to explore associations between IFCs and immune/cell death profiles. A Bayesian meta-analysis was further conducted to assess the impact of LNY in LUAD undergoing SR. Results: The survival analysis of our cohort demonstrated that increased LNY during SR did not prolong RFS (≥4 vs. <4 nodes: HR = 1.15; 95%CI: 0.76-1.74). A lower LNY during SR was associated with significantly better RFS in stage I LUAD receiving adjuvant immunochemotherapy (≥4 vs. <4 nodes: HR = 0.41; 95%CI: 0.17-0.94). In terms of IFCs, extensive lymph node dissection led to significantly increased levels of IL-6, IL-4, IL-10 and TNF-α after SR ( Discussion: Increased LNY during SR might confer no additional benefits to RFS for p-stage I LUAD. Excessive removal of LNs might exert adverse impact on physical sensitivity to immunochemotherapy. Personalized lymph node management should be adopted for selected node-negative disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.